slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 67,591-67,620
Pages 10,126
Rows per page 30
Component
67,591-67,620 of 303,780
13
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
14
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
15
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting Beat · Solution & ApproachLoop · Cost Of Inaction1 hit
23
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
24
The chart shows a clear shift in clinical trial focus toward oncology, increasing from 30% in 2016 to 48% in 2022.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
29
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
30
The slide uses a structured table to map trends to operational/technical complexity and their specific implications.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
37
The slide uses a visual bridge to connect the 'Likely'/'Highly Likely' and 'Unlikely'/'Not Possible' segments of the survey to their respective rationales.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
38
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
47
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
49
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
50
The slide presents qualitative interview profiles and quantitative survey respondent demographics.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
52
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
53
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
55
The slide serves as a corporate profile/introduction.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
56
This is a resource/reference slide listing various publications.Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
57
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
58
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development ReportPivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · L.E.K.
Consulting deck Strategy consulting 1 hit
02
The slide uses a structured table format to map market drivers to their specific impacts.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Situation & ContextLoop · Logic Chain1 hit
03
The chart is a waterfall representation of survey responses regarding future IT outsourcing spend.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Situation & ContextLoop · Logic Chain1 hit
04
The chart uses a stacked bar format to illustrate market growth across three segments: ITO, BPO, and Application development.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Logic Chain1 hit
05
The chart shows a bridge from 100 to 92, with a +5 increase and a -13 decrease.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Problem & ComplicationLoop · Logic Chain1 hit
06
The slide highlights a shift in spending towards specialized IT services.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Evidence & ProofLoop · Logic Chain1 hit
07
The slide uses a 100% stacked bar chart to show the shift in revenue mix and its impact on operating profit.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Evidence & ProofLoop · Logic Chain1 hit
08
The slide uses a simple list-in-table format to present strategic imperatives.Steering Clear of the IT Danger Zones · L.E.K.
Consulting deck Strategy consulting Beat · Impact & Next StepsLoop · Logic Chain1 hit
01
RAS likely stands for Robotic Assisted Surgery given the image of a surgical robot.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
02
The slide uses a maturity model/spectrum framework to show the evolution of surgical technology.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Situation & Context1 hit
04
The slide highlights 'Soft tissue surgical robots' as the focus of the report using a dashed orange box.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
05
The chart uses bubble size to represent the number of global surgical procedures and position on the curve to represent penetration level.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit
06
The slide uses a bar chart to visualize market growth and a callout box to highlight the projected market value.What is and how to navigate the RAS opportunity in LatAm? · L.E.K.
Consulting deck Strategy consulting Beat · Problem & Complication1 hit